Clinical trials in the US are slow, costly, and often out of reach for patients who might benefit from participation. 1Day Sooner and 18 organizations, 13 of them rare disease groups, are backing the bipartisan Faster Clinical Trials Act from @RepAuchincloss and @RepMGriffith.
There's a lot to focus on right now, but "The richest man to ever live just spent $200 million to support the Republican Senate candidate in Texas, and his man lost by double-digits in a statewide wipeout" is a completely insane sentence.
Put another way, the most expensive US Senate race before 2020 was $200 million. *One guy* spent that amount in Texas, and it doesn't seem to have made any difference. It might have hurt in a kind of Streisand effect way, in that the spending level was seen as obscene to people sympathetic to the argument that billionaires shouldn't "buy" elections.
The implications here seem pretty interesting! Especially re the limits of billionaire political power and/or the diminishing returns of money in politics.
Evidence is growing that we’re turning the corner on productivity.
US productivity grew at a 3.6% annual rate this past quarter.
That’s more than double the 1.5% average from 2007-2019.
The new numbers put me further ahead for my bet with Bob Gordon about productivity growth in the 2020s. 💪
Here’s how far the US is now ahead of the CBO estimate at the start of the decade (before they knew about the pandemic or LLMs) courtesy of @jasonfurman’s
Econvitals.
More of a hope than a proven assumption at this point, I’d say.
Seems plausible, though, that AI might generate some awesome breakthroughs.
Like CHO in the 80s, some of these might look “weird”.
If investors do not fund the weird-looking ideas, though, we’ll never know if they are both weird and good, like CHO turned out to be.
Thoughtful piece from @LifeSciVC (link in replies)
But Bruce’s causal story seems backwards to me: most *observable* AI-designed drug molecules are me-too’s precisely because that’s what VCs and big pharma prefer to fund!
It’s survivorship bias: the hypothetical full data set is quietly censored at the funding stage by investors, most of whom are skittish about novel target risk.
The best cultural criticism is impossible to unsee: the comparisons are so obviously true that once explained, they set in the back of one's minds forever. It almost feels like they have always been there, that they are obvious. So it is with Sitte, and with this excellent piece about his guide to building wonderful cities.
Biotech companies will materially change their form and shape. Old structures are gone. But AI is a massive injection of new capital into drug dev and biotech. Start a biotech company - just a very different one from before. $XBI
@EganPeltan It just comes down to structural factors: wages, the number of people, the organization of the healthcare system, and SOC. Wages are low, despite essentially 0 difference in skill, hours are longer, SOC is bad+people are many → speeding enrollment.
@rtnarch@AAMortazavi A good MOA narrative arc is essential for fundraising, so the market surely supplies investors with more plausible ones than can be real
Agree with @varma_ashwin97 here — see this famous paper from a couple years ago challenging the simple story for the granddaddy of all ADCs (Adcetris): https://t.co/JqMpSBJ6Ai
Target-based discovery is obviously necessary for molecule design in siRNA and other biologics (though phenotypic responses are still unpredictable—a target is not an MOA) but not so easy to distinguish it from the narrative heuristic.
Otherwise clinical success rates would be higher post its rise, no?